Pharmacologic vitreolysis in diabetic retinopathy

Current Pharmaceutical Biotechnology

Volumn 12, Issue 3, 2011, Pages 406-409

  Abu El Asrar, Ahmed M ^a   Al Mezaine, Hani S ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Diabetic retinopathy; Hyaluronidase; Pharmacologic vitreolysis; Plasmin

Indexed keywords

CHONDROITIN SULFATE; COLLAGEN TYPE 11; COLLAGEN TYPE 2; COLLAGEN TYPE 5; COLLAGEN TYPE 9; DISPASE; ENZYME; HYALURONIDASE; N ACETYLGALACTOSAMINE 4 SULFATASE; NATTOKINASE; OCRIPLASMIN; PLASMIN; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; BIOCHEMISTRY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; HUMAN; MOLECULAR WEIGHT; PHARMACOLOGIC VITREOLYSIS; PHARMACOLOGICAL PROCEDURES; VITREOUS BODY; VITREOUS BODY DETACHMENT; VITREOUS HEMORRHAGE;

ANIMALS; DIABETIC RETINOPATHY; FIBRINOLYSIN; FIBRINOLYTIC AGENTS; HUMANS; HYALURONOGLUCOSAMINIDASE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; RETINA; SHEEP; VITRECTOMY; VITREOUS BODY; VITREOUS DETACHMENT;

OVIS;

EID: 79551673935     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111794480543     Document Type: Article

References (44)

1. rd; Klein, R. American Diabetes Association. Diabetic retinopathy. Diabetes Care, 2003, 26, 226-229.
2. Abu El-Asrar, A.M.; Al-Mezaine, H.S.; Ola, M.S. Changing paradigms in the treatment of diabetic retinopathy. Curr. Opin. Oph-thalmol., 2009, 20, 532-538.
3. Patel, J.I.; Tombran-Tink, J.; Hykin, P.G. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: implications for structural differences in macular profiles. Exp. Eye Res., 2006, 82, 798-806.
4. Stefánsson, E. Physiology of vitreous surgery. Graefe's Arch. Clin. Exp. Ophthalmol., 2009, 247, 147-163.
5. Akiba, J.; Arzabe, C.W.; Trempe, C.L. Posterior vitreous detachment and neovascularization in diabetic retinopathy. Ophthal-mol.,1990, 97, 889-891.
6. Trese, M.T. Enzymatic-assisted vitrectomy. Eye, 2002, 16, 365-368.
7. Gandorfer, A. Enzymatic vitreous disruption. Eye, 2008, 22, 1273-1277.
8. Russell, S.R.; Hageman, G.S. Optic disc, foveal, and extrafoveal damage due to surgical separation of the vitreous. Arch. Ophthal-mol., 2001, 119, 1653-1658.
9. Nasrallah, F.P.; Jalkh, A.E.; Van Coppenolle, F.; Kado, M.; Trempe, C.L.; McMeel, J.W.; Schepens, C.L. The role of the vitreous in diabetic macular edema. Ophthalmology, 1988, 95, 1335-1339.
10. Hikichi, T.; Fujio, N.; Akiba, J.; Azuma, Y.; Takahashi, M.; Yoshida, A. Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship in type II diabetes mellitus. Ophthalmology, 1997, 104, 473-478.
11. Gaucher, D.; Tadayoni, R.; Erginay, A.; Haouchine, B.; Gaudric, A.; Massin, P. Optical coherence tomography assessment of the vit-reoretinal relationship in diabetic macular edema. Am. J. Ophthal-mol., 2005,139, 807-813.
12. Ghazi, N.G.; Ciralsky, J.B.; Shah, S.M.; Campochiaro, P.A.; Haller, J.A. Optical coherence tomography findings in persistent diabetic macular edema: the vitreomacular interface. Am. J. Oph-thalmol., 2007, 144, 747-754.
13. Yamamoto, T.; Hitani, K.; Tsukahara, I.; Yamamoto, S.; Kawasaki, R.; Yamashita, H.; Takeuchi, S. Early postoperative retinal thickness changes and complications after vitrectomy for diabetic macu-lar edema. Am. J.Ophthalmol., 2003, 135, 14-19.
14. Kumagai, K.; Furukawa, M.; Ogino, N.; Larson, E.; Iwaki, M.; Tachi, N. Long-term follow-up of vitrectomy for diffuse nontrac-tional diabetic macular edema. Retina, 2009, 29, 464-472.
15. Patel, J.I.; Hykin, P.G.; Schadt, M.; Luong, V.; Fitzke, F.; Gregor, Z.J. Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema. Retina, 2006, 26, 5-13.
16. Yamamoto, T.; Hitani, K.; Sato, Y.; Yamashita, H.; Takeuchi, S. Vitrectomy for diabetic macular edema with and without internal limiting membrane removal. Ophthalmology, 2005, 219, 206-213.
17. Sebag, J. Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal diseases. Graefe's Arch. Clin. Exp. Oph-thalmol., 2004, 242, 690-698.
18. Sebag, J. Molecular biology of pharmacologic vitreolysis. Trans. Am. Ophthalmol. Soc., 2005, 103, 473-494.
19. Sebag, J. Pharmacologic vitreolysis - premise and promise of the first decade. Retina, 2009, 29, 871-874.
20. Ranchod, T.M.; Goldenberg, D.T.; Trese, M.T. Pharmacologic vitreodynamics. Int. Ophthalmol. Clin., 2009, 49, 135-140.
21. Gandorfer, A. Objective of pharmacologic vitreolysis. Dev. Oph-thalmol., 2009, 44, 1-6.
22. Bishop, P.N.; McLeod, D.; Reardon, A. Effects of hyaluronan lyase, hyaluronidase, and chondroitin ABC lyase on mammalian vitreous gel. Invest. Ophthalmol. Vis. Sci., 1999, 40, 2173-2178.
23. Hermel, M.; Schrage, N.F. Efficacy of plasmin enzymes and chon-droitinase ABC in creating posterior vitreous separation in the pig: a masked, placebo-controlled in vivo study. Graefe's Arch. Clin. Exp. Ophthalmol., 2007, 245, 399-406.
24. Quiram, P.A.; Leverenz, V.R.; Baker, R.M.; Dang, L.; Giblin, F.J.; Trese, M.T. Microplasmin-induced posterior vitreous detachment affects vitreous oxygen levels. Retina, 2007, 27, 1090-1096.
25. Wang Z.L.; Zhang, X.; Xu, X.; Sun, X.D.; Wang, F. PVD following plasmin but not hyaluronidase: implications for combination pharmacologic vitreolysis therapy. Retina, 2005, 25, 38-43.
26. Hikichi, T.; Kado, M.; Yoshida, A. Intravitreal injection of hyaluronidase cannot induce posterior vitreous detachment in the rabbit. Retina, 2000, 20,195-198.
27. Takano, A.; Hirata, A.; Ogasawara, K.; Sagara, N.; Inomata, Y.; Kawaji, T.; Tanihara, H. Posterior vitreous detachment induced by nattokinase (subtilisin NAT): a novel enzyme for pharmacologic vitreolysis. Invest. Ophthalmol. Vis. Sci., 2006, 47, 2075-2079.
28. Wang, F.; Wang, Z.; Sun, X.; Wang, F.; Xu, X.; Zhang, X. Safety and efficacy of dispase and plasmin in pharmacologic vitreolysis. Invest. Ophthalmol. Vis. Sci., 2004, 45, 3286-3290.
29. Li, X.; Shi, X.; Fan, J. Posterior vitreous detachment with plasmin in the isolated human eye. Graefe's Arch. Clin. Exp. Ophthalmol., 2002, 240, 56-62.
30. Nagai, N.; Demarsin, E.; Van Hoef, B.; Wouters, S.; Cingolani, D.; Laroche, Y.; Collen, D. Recombinant human microplasmin: production and potential therapeutic properties. J. Thromb. Haemost., 2003, 1, 307-313.
31. Chen, W.; Huang, X.; Ma, X.W.; Mo, W.; Wang, W.J.; Song, H.Y. Enzymatic vitreolysis with recombinant microplasminogen and tissue plasminogen activator. Eye, 2008, 22,300-307.
32. de Smet, M.D.; Valmaggia, C.; Zarranz-Ventura, J.; Willekens, B. Microplasmin-ex vivo characterization of its activity in porcine vitreous. Invest.Ophthalmol. Vis. Sci., 2009, 50, 814-819.
33. Gandorfer, A.; Rohleder, M.; Sethi, C.; Eckle, D.; Welge-Lüssen, U.; Kampik, A.; Luthert, P.; Charteris, D. Posterior vitreous detachment induced by microplasmin. Invest. Ophthalmol. Vis. Sci., 2004, 45, 641-647.
34. Sakuma, T.; Tanaka, M.; Mizota, A.; Inoue, J.; Pakola, S. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes. Invest. Ophthalmol. Vis. Sci., 2005,46, 3295-3299.
35. Chen, W.; Mo, W.; Sun, K.; Huang, X.; Zhang, Y.L.; Song, H.Y. Microplasmin degrades fibronectin and laminin at vitreoretinal interface and outer retina during enzymatic vitrectomy. Curr. Eye Res., 2009, 34,1057-1064.
36. Kuppermann, B.D.; Thomas, E.L.; de Smet, M.D.; Grillone, L.R. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (vitrase) for the management of vitreous hemorrhage. Am. J.Ophthalmol., 2005, 140, 573-584.
37. Kuppermann, B.D.; Thomas, E.L.; de Smet, M.D.; Grillone, L.R. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (vitrase) for the management of vitreous hemorrhage. Am. J.Ophthalmol., 2005, 140, 585-597.
38. Zhi-Liang, W.; Wo-Dong, S.; Min, L.; Xiao-Ping, B.; Jin, J. Phar-macologic vitreolysis with plasmin and hyaluronidase in diabetic rats. Retina, 2009, 29, 269-274.
39. Sakuma, T.; Tanaka, M.; Inoue, J.; Mizota, A.; Souri, M.; Ichinose, A. Use of autologous plasmin during vitrectomy for diabetic macu-lopathy. Eur. J. Ophthalmol., 2006, 16, 138-140.
40. Azzolini, C.; D'Angelo, A.; Maestranzi, G.; Codenotti, M.; Della Valle, P.; Prati, M.; Brancato, R. Intrasurgical plasmin enzyme in diabetic macular edema. Am. J. Ophthalmol., 2004, 138, 560-566.
41. Asami, T.; Terasaki, H.; Kachi, S.; Nakamura, M.; Yamamura, K.; Nabeshima, T.; Miyake, Y. Ultrastructure of internal limiting membrane removed during plasmin-assisted vitrectomy from eyes with diabetic macular edema. Ophthalmology, 2004, 111, 231-237.
42. Williams, J.G.; Trese, M.T.; Williams, G.A.; Hartzer, M.K. Autologous plasmin enzyme in the surgical management of diabetic retinopathy. Ophthalmology, 2001, 108,1902-1905.
43. Hirata, A.; Takano, A.; Inomata, Y.; Yonemura, N.; Sagara, N.; Tanihara, H. Plasmin-assisted vitrectomy for management of pro-liferative membrane in proliferative diabetic retinopathy: A pilot study. Retina, 2007, 27,1074-1078.
44. Diaz-Llopis, M.; Udaondo, P.; Arevalo, F.; Salom, D.; Garcia-Delpech, S.; Quijada, A.; Romero, F.J. Intravitreal plasmin without associated vitrectomy as a treatment of refractory diabetic macular edema. J. Ocul. Pharmacol. Ther., 2009, 25, 379-384.